UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000024464 |
|---|---|
| Receipt number | R000028155 |
| Scientific Title | Confirmation trial for the ameliorating effects of lactobacillus acidophilus strain L-92 on borderline symptoms of perennial allergic rhinitis |
| Date of disclosure of the study information | 2016/10/19 |
| Last modified on | 2017/02/21 15:56:31 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Confirmation trial for the ameliorating effects of lactobacillus acidophilus strain L-92 on borderline symptoms of perennial allergic rhinitis
Acronym
Confirmation trial for the ameliorating effects of lactobacillus acidophilus strain L-92 on borderline symptoms of perennial allergic rhinitis
Scientific Title
Confirmation trial for the ameliorating effects of lactobacillus acidophilus strain L-92 on borderline symptoms of perennial allergic rhinitis
Scientific Title:Acronym
Confirmation trial for the ameliorating effects of lactobacillus acidophilus strain L-92 on borderline symptoms of perennial allergic rhinitis
Region
| Japan |
Condition
Condition
Healthy Adult
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the ameliorating effects of lactobacillus acidophilus strain L-92 on borderline symptoms of perennial allergic rhinitis
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Amelioration in subjective symptoms of perennial allergic rhinitis after 4 or 8 weeks intervention
Key secondary outcomes
After 4 or 8 weeks intervention, local findings, antigen-specific IgE(house dust, Dermatophagoides pteronyssinus, Dermatophagoides farinae, night fly, animal epithelial, total IgE), questionnaires on subjective symptoms, medical interview(including findings), body weight, body height, BMI, blood pressure, pulse rate, Blood tests(leukocyte count, erythrocyte count, hemoglobin, hematocrit, platelet count, MCV, MCH, MCHC, leukocyte picture, total protein, albumin, AST(GOT), ALT(GPT), LD(LDH), total bilirubin, ALP, g-GT(g-GTP), CK(CPK), urea nitrogen(UN), uric acid level, creatinine, Na, Cl, K, Ca, total cholesterol, LDL-cholesterol, HDL-cholesterol, TG(neutral fat), fasting blood sugar, HbA1c, insulin, urinary test(protein, sugar, occult blood reaction, urobilinogen, pH, specific gravity)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Daily intakes of tablets including Lactobacillus acidophilus strain L-92 for 8 weeks
Interventions/Control_2
Daily intakes of tablets not including Lactobacillus acidophilus strain L-92 for 8 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.Healthy adult who have a discomfort in eyes and noses by house dust in daily life.
2.Suffering from borderline symptoms of perennial allergic rhinitis.
3.Getting a positive for specific IgE against house dust in the screening test.
4.Not interpreted positive by the principal investigator as a result of specific IgE against seasonal antigens in the screening test.
5.Suffering from borderline symptoms of perennial allergic rhinitis interpreted by the principal investigator from weekly symptoms before screening test.
6.Giving priority to those who have edema in the mucous of inferior nasal concha.
7.Being informed fully about the purpose and the contents of the clinical trial and having the ability to consent. Those who hope spontaneously with understanding of the trial and consent to take part in the trial in writing.
Key exclusion criteria
1.Suffering from a disease requiring treatment urgently, and having a chronic disease except for perennial allergic rhinitis.
2.Suffering from acute rhinitis, paranasal sinusitis, nasal polyp, hypertrophic rhinitis, deflected septum.
3.Being associated with bronchial asthma.
4.Suffering from serious disease of liver, kidney, heart, respiratory apparatus, internal secretion, or metabolism.
5.Practicing specific hyposensitization therapy.
6.Using oral medicines or nose drops such as antihistamine or anti-allergic agent, and using other medicines.
7.Daily intakes of preparations or supplements including lactic acid bacteria.
8.Daily intakes of yogurt or foods which have the effect of anti-allergy such as Tencha(sweet tea).
9.Suspected to be allergic to ingredients of the test material.
10.Being pregnant, likely to be pregnant, or breast-feeding.
11.Participants in other clinical tests like having foods or using medicines. Participants in other clinical tests like putting on cosmetics or medical application.
12.Participants or likely to be participants in other clinical tests within a month before getting consent.
13.Being interpreted unsuitable for a subject by the principal investigator.
Target sample size
160
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tsugutami Onodera |
Organization
Sapporo Yurinokai Hospital
Division name
Director
Zip code
Address
11-186 Yurigahara, Kita-ku, Sapporo, Hokkaido
TEL
011-771-1501
takahashi@yurinokaihp.or.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yoshika Komori |
Organization
KSO Corporation
Division name
Sales department
Zip code
Address
1-9-7 Shibaura, Minato-ku, Tokyo
TEL
03-3452-7733
Homepage URL
yoshi@kso.co.jp
Sponsor or person
Institute
Sapporo Yurinokai Hospital
Institute
Department
Personal name
Funding Source
Organization
Asahi Group Holdings, Ltd
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 10 | Month | 19 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2016 | Year | 08 | Month | 29 | Day |
Date of IRB
Anticipated trial start date
| 2016 | Year | 10 | Month | 19 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 10 | Month | 18 | Day |
Last modified on
| 2017 | Year | 02 | Month | 21 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028155
